Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
        • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
      • Recently Published Guidelines
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
      • Brigham and Women's Hospital
      • Hartford Hospital
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Instituto do Coração-INCOR (São Paulo, Brasil)
      • Minneapolis City Hospital
      • Parkland Hospital: Dallas, Texas
      • Pennsylvania Hospital, Philadelphia
      • Pitié-Salpêtrière Hospital
      • Royal Infirmary of Edinburgh, Scotland
      • Tufts Medical Center
      • University of Michigan
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
      • Women's College Hospital, Toronto, Canada
      • Henry Ford Hospital, Detroit, Michigan
      • Instituto Nacional de Cardiología Ignacio Chávez – INCICh México City, México
      • Kuang-Tien General Hospital (Taichug, Taiwan)
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Basic Science Reports

β-Adrenoceptor Blocker Carvedilol Provides Cardioprotection via an Adenosine-Dependent Mechanism in Ischemic Canine Hearts

Hiroshi Asanuma, Tetsuo Minamino, Shoji Sanada, Seiji Takashima, Hisakazu Ogita, Akiko Ogai, Masanori Asakura, Yulin Liao, Yoshihiro Asano, Yasunori Shintani, Jiyoong Kim, Yoshiro Shinozaki, Hidezo Mori, Koichi Node, Soichiro Kitamura, Hitonobu Tomoike, Masatsugu Hori, Masafumi Kitakaze
Download PDF
https://doi.org/10.1161/01.CIR.0000130917.12959.04
Circulation. 2004;109:2773-2779
Originally published June 7, 2004
Hiroshi Asanuma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuo Minamino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoji Sanada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiji Takashima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisakazu Ogita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akiko Ogai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masanori Asakura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yulin Liao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihiro Asano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasunori Shintani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiyoong Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiro Shinozaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hidezo Mori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koichi Node
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soichiro Kitamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hitonobu Tomoike
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masatsugu Hori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masafumi Kitakaze
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Background— Carvedilol is a β-adrenoceptor blocker with a vasodilatory action that is more effective for the treatment of congestive heart failure than other β-blockers. Recently, carvedilol has been reported to reduce oxidative stress, which may consequently reduce the deactivation of adenosine-producing enzymes and increase cardiac adenosine levels. Therefore, carvedilol may also have a protective effect on ischemia and reperfusion injury, because adenosine mediates cardioprotection in ischemic hearts.

Methods and Results— In anesthetized dogs, the left anterior descending coronary artery was occluded for 90 minutes, followed by reperfusion for 6 hours. Carvedilol reduced the infarct size (15.0±2.8% versus 40.9±4.2% in controls), and this effect was completely reversed by the nonselective adenosine receptor antagonist 8-sulfophenyltheophylline (45.2±5.4%) or by an inhibitor of ecto-5′-nucleotidase (44.4±3.6%). There were no differences of either area at risk or collateral flow among the various groups. When the coronary perfusion pressure was reduced in other dogs so that coronary blood flow was decreased to 50% of the nonischemic level, carvedilol increased coronary blood flow (49.4±5.6 to 73.5±7.5 mL · 100 g−1 · min−1; P<0.05) and adenosine release (112.3±22.2 to 240.6±57.1 nmol/L; P<0.05) during coronary hypoperfusion. This increase of coronary blood flow was attenuated by either 8-sulfophenyltheophylline or superoxide dismutase. In human umbilical vein endothelial cells cultured with or without xanthine and xanthine oxidase, carvedilol caused an increase of ecto-5′-nucleotidase activity.

Conclusions— Carvedilol shows a cardioprotective effect against ischemia and/or reperfusion injury via adenosine-dependent mechanisms.

  • adenosine
  • stress
  • ischemia
  • reperfusion
  • infarction

Received July 23, 2003; de novo received December 18, 2003; revision received February 18, 2004; accepted February 25, 2004.

Beta-adrenoceptor antagonists (β-blockers) are used for the treatment of ischemic heart disease because these drugs reduce adrenergic activity.1,2 Carvedilol is a β-blocker that has shown efficacy for chronic heart failure in several large-scale trials.3,4 Carvedilol decreases vascular resistance3 and improves the pathophysiology of chronic heart failure.5 This drug dilates both systemic and coronary vessels,6 which is not a typical characteristic of β-blockers. Although this vasodilatory action may contribute to the beneficial effects of carvedilol in ischemic or nonischemic heart failure,5 it may not be the primary mechanism of cardioprotection, because vasodilators are not always effective at protecting the heart.7 Interestingly, carvedilol can also reduce oxidative stress,8 which causes cellular damage through inactivation of membrane enzymes, pumps, and proteins, such as Na+/K+-ATPase,9 Ca2+ channels,10 and ecto-5′-nucleotidase.11 Ecto-5′-nucleotidase is the enzyme that produces adenosine, and adenosine is believed to ameliorate chronic heart failure or myocardial ischemia.12

To investigate the relationship between the cardioprotective effect of carvedilol and the reduction of oxidative stress on the enhancement of adenosine release, we examined whether carvedilol could reduce infarct size via adenosine- or ecto-5′-nucleotidase–dependent mechanisms in canine hearts. We also investigated whether carvedilol could increase coronary blood flow (CBF) via attenuation of oxidative stress and enhancement of adenosine release in ischemic canine hearts.

Methods

Instrumentation

We have previously reported the details of the instrumentation procedure.13 In brief, hybrid dogs (HBD) mated with the beagle, American fox hound, and Labrador retriever for laboratory use (weighing 15 to 21 kg; Kitayama Labes, Gifu, Japan) were anesthetized by an intravenous injection of sodium pentobarbital (30 mg/kg), intubated, and ventilated with room air mixed with oxygen (100% O2 at flow rate of 1.0 to 1.5 L/min). The arterial blood pH, Po2, and Pco2 before the protocol was begun were 7.38±0.02, 104±3 mm Hg, and 38.7±1.6 mm Hg, respectively. End-diastolic length (EDL) was determined at the R wave on the ECG, and end-systolic length (ESL) was determined at the minimum pressure differential. Then, fractional shortening (FS) was calculated as [(EDL−ESL)/EDL]×100%. Agents were administered into the left anterior descending coronary artery (LAD) via the bypass tube. To constitute the coronary bypass between the carotid artery and the LAD, <30 seconds interruption of the LAD was necessary, but this brief period of ischemia does not provoke either myocardial injury or protection. This study conformed to the Position of the American Heart Association on Research Animal Use adopted by the Association in November 1984.

Experimental Protocols

Protocol 1: Effects of Carvedilol on Adenosine Release and CBF in Nonischemic Myocardium

After hemodynamics became stable, coronary arterial and venous blood samples were obtained for the measurement of adenosine concentrations,11 and the difference between the adenosine levels in coronary arterial and venous blood [VAD(Ado)] was then calculated.

Five HBD dogs were used in protocol 1. Hemodynamic parameters (ie, systolic and diastolic aortic blood pressure and heart rate) were monitored. Carvedilol was infused at 1.5 μg · kg−1 · min−1 (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 0.09 mg/mL) for 10 minutes, and then coronary perfusion pressure (CPP), CBF, FS, and VAD(Ado) were measured. Carvedilol was dissolved in a small volume of DMSO (final concentration, <0.15%). In a preliminary study, this dose of carvedilol was shown to be the minimum dose that caused maximal coronary vasodilation in ischemic or nonischemic hearts. We also confirmed that this volume of DMSO did not change either coronary hemodynamics or VAD(Ado) in ischemic or nonischemic hearts.

Protocol 2: Effects of Carvedilol or Propranolol on Adenosine Release and CBF in Ischemic Hearts

After hemodynamics became stable, coronary arterial and venous blood samples were obtained for blood gas analysis and for measurement of adenosine11,13 and lactate14 levels. Lactate extraction ratio (LER) was calculated as the coronary arteriovenous difference of the lactate concentration multiplied by 100 and divided by the arterial lactate concentration.

Twenty HBD dogs were used in protocol 2. Hemodynamic parameters were monitored. To examine whether administration of carvedilol caused coronary vasodilation and reduced the severity of myocardial ischemia and whether adenosine-dependent mechanisms are involved in these actions, saline (n=5), α,β-methyleneadenosine diphosphate (AMP-CP) at 80 μg · kg−1 · min−1 (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 4.8 mg/mL, n=5), or 8-sulfophenyltheophylline (8-SPT) at 30 μg · kg−1 · min−1 (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 1.8 mg/mL, n=5) was infused into the bypass tube. AMP-CP is an inhibitor of ecto-5′-nucleotidase, whereas 8-SPT is a nonspecific adenosine receptor antagonist. Both agents were dissolved in saline before administration. After confirming that systemic and coronary hemodynamics were unchanged for 5 minutes after each drug infusion, CPP was reduced so that CBF decreased to 50% of the baseline level for 5 minutes. Then, infusion of carvedilol was started at 1.5 μg · kg−1 · min−1 (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 0.09 mg/mL) and was continued for 10 minutes, while CPP was maintained at the reduced level. A preliminary study showed that the above-mentioned dose of 8-SPT was the minimum dose that prevented coronary vasodilation induced by adenosine at 2 μg · kg−1 · min−1, whereas the dose of carvedilol (1.5 μg · kg−1 · min−1) was the minimum level that caused maximal coronary vasodilation.

In addition, propranolol was infused at 30 μg · kg−1 · min−1 (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 1.8 mg/mL) to investigate whether it had effects identical to those of carvedilol (n=5). This dose of propranolol corresponds to 15 μg/mL, and the effective dose of propranolol is >10 μg/mL, indicating that the dose of propranolol in the present study is sufficient to antagonize β-receptors of the hearts.

Protocol 3: Influence of the Antioxidant Activity of Carvedilol on CBF

To examine whether carvedilol eliminates oxidative stress and causes adenosine-dependent coronary vasodilation in ischemic hearts, either saline (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 1.5 mg/mL, n=5) or human recombinant superoxide dismutase (SOD) (5340 IU/mg, >99% purity) at 25 μg · kg−1 · min−1 (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 1.5 mg/mL, n=5) was infused into the bypass tube. CPP was then reduced so that CBF decreased to 50% of the baseline level for 5 minutes. Subsequently, infusion of carvedilol at 1.5 μg · kg−1 · min−1 (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 0.09 mg/mL) was initiated and continued for 10 minutes, while CPP was maintained at the reduced value. As a marker of oxidative stress, the 8-iso-prostaglandin F2α level was measured in coronary arterial and venous blood, and the arteriovenous difference of 8-iso-prostaglandin F2α [VAD(8-Iso-F2α)] was calculated. We confirmed that this dose of SOD had no effect on either systemic or coronary hemodynamic parameters.11

Protocol 4: Effects of Carvedilol on Infarct Size After 90 Minutes of Ischemia

In HBD dogs, the bypass tube to the LAD was occluded for 90 minutes, followed by reperfusion for 6 hours, together with administration of either saline (n=7, control) or DMSO (0.0167 mL · kg−1 · min−1, n=5) from 10 minutes before occlusion until 1 hour of reperfusion, except at the time of coronary occlusion. Hemodynamic parameters were monitored during myocardial ischemia and after the start of reperfusion. In the carvedilol group (n=5), carvedilol at 1.5 μg · kg−1 · min−1 (an infusion rate of 0.0167 mL · kg−1 · min−1 at a concentration of 0.09 mg/mL) was infused from 10 minutes before coronary occlusion until 60 minutes after the start of reperfusion, except during occlusion. In the carvedilol+8-SPT group (n=6) and the carvedilol+AMP-CP group (n=6), the effect of carvedilol was tested during concomitant administration of either 8-SPT at 30 μg · kg−1 · min−1 or AMP-CP at 80 μg · kg−1 · min−1. In the 8-SPT group (n=6) and the AMP-CP group (n=7), 90 minutes of ischemia and 6 hours of reperfusion were performed during treatments with 8-SPT and AMP-CP, respectively. Either 8-SPT or AMP-CP was infused from 10 minutes before coronary occlusion until 60 minutes after the start of reperfusion, except during occlusion. In all groups, infarct size was assessed after 6 hours of reperfusion.

Protocol 5: Effects of Carvedilol on 5′-Nucleotidase Activity

In human umbilical vein endothelial cells (HUVECs) cultured with or without xanthine (1×10−4 mol/L) and xanthine oxidase (1.6×10−3 U/mL), 5′-nucleotidase activity was measured by an enzyme assay after exposure to carvedilol (0, 1×10−8 to 1×10−5 mol/L) for 15 minutes.15

Analyses

The methods of measuring plasma adenosine levels,11 myocardial ecto-5′-nucleotidase activity,11,16 and plasma lactate levels13 have been reported previously.

Measurement of Infarct Size and Collateral Blood Flow

In protocol 4, the area of myocardial necrosis and the area at risk16 were measured in all of the dogs upon completion of the protocol by an operator who had no knowledge of the treatment given to each animal. Infarct size was expressed as a percentage of the area at risk.

Regional myocardial blood flow was determined as described previously.17 Nonradioactive microspheres (Sekisui Plastic Co) made of inert plastic were labeled with bromine. Microspheres were administered at 80 minutes after the start of coronary occlusion. The radio fluorescence of the stable heavy elements was measured with a wavelength dispersive spectrometer (PW 1480, Phillips Co). Because the level of energy emitted is characteristic of specific elements, it was possible to quantify the radio fluorescence of the heavy element with which the microspheres were labeled. Myocardial blood flow was calculated according to the following formula: time flow=(tissue count)×(reference flow)/(reference count), and was expressed in milliliters per minute per gram wet weight. Endomyocardial blood flow was measured at the inner half of the left ventricular wall.

Exclusion Criteria

To ensure that all of the animals used for analysis of infarct size in protocol 4 were healthy and were exposed to a similar extent of ischemia, the following standards were used for exclusion of unsatisfactory dogs: (1) subendocardial collateral blood flow >15 mL · 100 g−1 · min−1, (2) a heart rate >170 bpm, and (3) >2 consecutive attempts required to terminate ventricular fibrillation using low-energy DC pulses applied directly to the heart.

Statistical Analysis

Statistical analysis was performed by use of ANOVA18,19 to compare data among the groups. When ANOVA indicated a significant difference, paired data were compared by use of the Bonferroni test. Changes of the hemodynamic and metabolic parameters over time were assessed by ANOVA with repeated measures. Results were expressed as the mean±SEM, with a value of P<0.05 being considered significant.

Results

Effects of Carvedilol on VAD(Ado) in Nonischemic Myocardium

Neither systemic hemodynamic parameters (mean blood pressure, 101.0±2.1 versus 98.6±3.2 mm Hg and heart rate, 130.2±3.7 versus 128.0±3.3 bpm) nor FS (20.1±1.0% versus 21.5±1.0%) changed during the infusion of carvedilol. In contrast, CBF was increased (98.4±8.5 versus 112.6±9.6 mL · 100 g−1 · min−1, P<0.05), as was VAD(Ado) (40.9±4.0 versus 68.6±5.5 nmol/L, P<0.05).

Effects of Either Carvedilol or Propranolol on VAD(Ado) During Coronary Hypoperfusion

Administration of either 8-SPT or AMP-CP did not alter the systemic hemodynamics (mean blood pressure, 98.8±6.1 versus 101.8±5.8 mm Hg before and after 8-SPT and 99.0±3.0 versus 102.0±3.2 mm Hg before and after AMP-CP; heart rate, 132.2±6.9 versus 132.4±6.1 min−1 before and after 8-SPT and 131.8±4.6 versus 132.8±3.4 min−1 before and after AMP-CP) or the coronary hemodynamic and metabolic parameters (Figures 1 through 3⇓⇓). Before both CBF and CPP were reduced, there were no significant differences in hemodynamic and metabolic parameters among the 3 groups. In untreated dogs, administration of saline did not affect CPP, LER, or FS. However, addition of carvedilol increased VAD(Ado), CBF, LER, and FS, even in the constant low-CPP state, suggesting that myocardial ischemia was improved by carvedilol. These effects of carvedilol were blunted by administration of either 8-SPT or AMP-CP. Unlike carvedilol, an infusion of propranolol did not alter VAD(Ado), CBF, LER, or FS (Figures 1 through 3⇓⇓).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Effects of carvedilol on coronary hemodynamics in ischemic myocardium. A and B show CPP and CBF, respectively. Statistical analysis was performed by ANOVA followed by Bonferroni’s test.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Changes of difference in adenosine levels between coronary venous and arterial blood [VAD(Ado)] in ischemic myocardium. Carvedilol increased VAD(Ado), which was attenuated by an ecto-5′-nucleotidase inhibitor. Statistical analysis was performed by ANOVA followed by Bonferroni’s test.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Changes of FS (A) and LER (B) in ischemic myocardium. Statistical analysis was performed by ANOVA followed by Bonferroni’s test.

Reduction of Oxidative Stress and Beneficial Effect of Carvedilol in Ischemic Myocardium

In 5 dogs, reduction of CBF caused an increase of VAD(8-Iso-F2α), which was reduced by carvedilol (Figure 4A through 4C). Under these conditions, VAD(Ado) was increased by infusion of carvedilol (Figure 4D). In another 5 dogs, an infusion of SOD did not change either hemodynamic parameters or VAD(8-Iso-F2α) at nonischemic baseline conditions (Figure 4A through 4C). After the reduction of CBF to 50%, VAD(Ado) increased to the level seen in the presence of carvedilol without SOD (Figure 4D), whereas VAD(8-Iso-F2α) did not increase (Figure 4C). Addition of carvedilol did not further attenuate VAD(8-Iso-F2α) or increase VAD(Ado) (Figure 4C and 4D).

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. Changes of CPP (A), CBF (B), VAD(8-Iso-F2α) (C), and VAD(Ado) (D) in ischemic myocardium. Statistical significance was tested by ANOVA followed by Bonferroni’s test.

Effects of Carvedilol on Infarct Size

Seven of 64 dogs were excluded from analysis because their subendocardial collateral flow was >15 mL · 100 g−1 · min−1, so 57 dogs completed the protocol satisfactorily. Among these 57 dogs, 18 dogs developed ventricular fibrillation at least once, and ventricular fibrillation that matched the exclusion criteria occurred in 15 dogs, so these animals were also excluded from analysis. The numbers of the dogs that met the exclusion criteria of ventricular fibrillation were 2, 2, 0, 2, 3, 3, and 3 in the saline, the DMSO, the carvedilol, the carvedilol+8-SPT, the carvedilol+AMP-CP, the 8-SPT, and the AMP-CP groups, respectively.

Neither aortic blood pressure (≈104 mm Hg) nor heart rate (≈136 min−1) showed any differences among the 7 groups throughout the protocol. The Table shows the area at risk and the endocardial collateral blood flow in the LAD region during myocardial ischemia. There were no significant differences in the area at risk and collateral flow among the 7 groups during myocardial ischemia (Table). Figure 5 shows that carvedilol decreased infarct size compared with the control groups. This protective effect was completely blocked by either 8-SPT or AMP-CP, suggesting that the reduction of infarct size by carvedilol was attributable to an adenosine-dependent mechanism.

View this table:
  • View inline
  • View popup

Area at Risk and Collateral Blood Flow During Myocardial Ischemia in Each Group

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 5. Infarct size as a percentage of area at risk. Infarct size was decreased in carvedilol group compared with control group, and this improvement was blocked by either 8-SPT or AMP-CP. Statistical significance was tested by ANOVA followed by Bonferroni’s test.

Effect of Carvedilol on Ecto-5′-Nucleotidase Activity in HUVECs

In HUVECs, carvedilol increased ecto-5′-nucleotidase activity by 35.4±8.4% (P<0.01) (Figure 6A). Exposure to xanthine and xanthine oxidase decreased ecto-5′-nucleotidase activity, whereas concomitant addition of carvedilol restored ecto-5′-nucleotidase activity to 104.9±8.7% of the baseline levels (P<0.01) (Figure 6B). Neither carvedilol nor xanthine and xanthine oxidase had any effect on cytosolic 5′-nucleotidase.

Figure6
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 6. Ecto-5′-nucleotidase activity of HUVECs in presence or absence of carvedilol or xanthine and xanthine oxidase. Statistical significance was tested by ANOVA followed by Bonferroni’s test.

Discussion

In the present study, we demonstrated that carvedilol increases both adenosine release and CBF in ischemic and nonischemic hearts via reduction of oxidative stress and restoration of ecto-5′-nucleotidase activity. We also showed that carvedilol could limit infarct size and that this effect was attributable to the reduction of oxidative stress and an adenosine- or ecto-5′-nucleotidase–dependent mechanism. These findings suggested that the cardioprotective effect of carvedilol was attributable to an increase of adenosine in ischemic myocardium in addition to its β-blocking action, because propranolol did not mimic this effect.

Influence of Carvedilol on Adenosine Release in Ischemic Hearts

The β-adrenoreceptors in coronary smooth muscle are involved in coronary vasodilation, and their stimulation is thought to increase CBF via the relaxation of vascular smooth muscle and increased myocardial oxygen demand. Therefore, it may seem unusual that a β-blocker like carvedilol would cause coronary vasodilation. There are several possible explanations for the present findings. First, carvedilol itself may cause vasodilation separately from its β-blocking activity. Indeed, although carvedilol does not have a nitroxy moiety, its chemical structure predicts that the drug could also block α1-adrenoceptors,20 which would cause vasodilation. We cannot exclude this possibility, but the role of α1-adrenoceptor blockade in the vasodilatory effect of carvedilol seems likely to be minor, because we have previously reported that blockade of α1-adrenoceptors attenuates adenosine release in ischemic myocardium,21 whereas we found that carvedilol caused an increase of adenosine production. Second, carvedilol may increase vasodilatory substances such as NO or adenosine. We demonstrated that carvedilol could increase cardiac adenosine production independently of its β-blocking effect in the present study, because propranolol did not increase CBF under the same circumstances (Figures 1 through 3⇑⇑). Intriguingly, the carvedilol-induced increases in both adenosine release and coronary vasodilation were greater in ischemic heart than in nonischemic heart. There was a significant difference between the influence of carvedilol on coronary vasodilation under nonischemic and ischemic conditions in the present study, because the percent increases of CBF in nonischemic and ischemic myocardium were 14.4±1.1% and 50.6±10.1% (P<0.05), respectively. One possible explanation is that carvedilol may bind more tightly to β-adrenoreceptors under ischemic conditions than nonischemic conditions, and β-adrenoreceptors are also upregulated in the ischemic heart,22 which may enhance the adenosine-producing effect of carvedilol. Alternatively, even if carvedilol decreases coronary artery tone in nonischemic heart as well as ischemic heart, the activity of other endogenous vasodilators may decrease to maintain coronary autoregulation. Conversely, the effects of other vasodilators may already be maximal in ischemic hearts, so that carvedilol-induced adenosine release becomes a major determinant of coronary artery tone when adenosine-dependent coronary vasodilation is submaximal. A third possibility is that carvedilol may reduce the levels of substances that attenuate adenosine release and are increased in ischemic myocardium. Because carvedilol is reported to decrease oxidative stress and such stress reduces adenosine production, antioxidant activity of carvedilol may be involved in adenosine-dependent coronary vasodilation and cardioprotection. We showed such evidence in the present study.

In this context, several lines of evidence support the concept that adenosine can markedly attenuate ischemia/reperfusion injury,12,23 and we suggest that carvedilol-induced adenosine release is important for cardioprotection.

Mechanism of the Carvedilol-Induced Increase of Cardiac Adenosine

In ischemic hearts, carvedilol caused reduction of oxidative stress and increases in both adenosine release and CBF. Also, in HUVECs under oxidative stress, carvedilol restored ecto-5′-nucleotidase activity to the control level. These findings suggest that carvedilol may eliminate the factors that impaired ecto-5′-nucleotidase activity under ischemic conditions. Oxidative stress is one of these factors. Because oxygen-derived free radicals attenuate the ischemia-induced activation of ecto-5′-nucleotidase, elimination of oxidative stress may increase adenosine release in the ischemic myocardium. We observed that carvedilol could reduce oxidative stress, so this action may explain the present findings. Because ecto-5′-nucleotidase is susceptible to impairment by oxygen-derived free radicals, it is likely that the beneficial effect of carvedilol on myocardial ischemia in the present study was attributable to its antioxidant activity.

Clinical Relevance and Limitations

Carvedilol has been shown to be effective for treating heart failure.5 Its effective clinical dose is about 0.1 to 0.2 μg/mL, and the calculated cardiac concentration of carvedilol in the present study is ≈1 μg/mL. In dogs, carvedilol at 1 and 4 μg/mL decreased blood pressure by 9% and 32%, respectively (data not shown), suggesting that the concentration of 1 μg/mL of carvedilol in canine heats was comparable to a clinical dose of carvedilol. This difference may be also attributable to species differences, the route of administration of carvedilol, or conscious/anesthetic conditions.

The present study hinted that the mechanism by which carvedilol potently ameliorates heart failure, especially ischemic heart failure, may be related to adenosine.12 Carvedilol may have the ability to both antagonize β-adrenoceptors and increase adenosine release.

Tumor necrosis factor-α is inhibited by both carvedilol and adenosine24,25 and has been indicated to have a role in the pathology of congestive heart failure. Because the present study hints that the cardioprotection afforded by carvedilol is adenosine-dependent, it follows that the clinical effects of carvedilol may also be adenosine-dependent. If this hypothesis receives further validation, adenosine and potentiators of adenosine production or adenosine receptor agonists may become candidates for the treatment of heart failure.

Acknowledgments

This study was supported by Grants-in-aid for Scientific Research 12470153 and 12877107 from the Japanese Ministry of Education, Culture, Sports, Science, and Technology; a Health and Labor Sciences Research Grant for Human Genome, Tissue Engineering, and Food Biotechnology (H13-Genome-011); and a Health and Labor Sciences Research Grant for Comprehensive Research on Aging and Health (H13-21seiki(seikatsu)-23, H14Tokushitsu-38) from the Japanese Ministry of Health and Labor and Welfare. The authors gratefully acknowledge the technical assistance of Tomi Fukushima and Junko Yamada during the conduct of the experiments.

References

  1. ↵
    Saxenhofer H, Morger D, Weidmann P, et al. Modulation of noradrenergic but not angiotensinergic blood pressure control by beta-blockade with carteolol. J Hypertens. 1991; 9: 1049–1056.
    OpenUrlCrossRefPubMed
  2. ↵
    Silke B, Verma SP, Hussain M, et al. Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris. Br J Clin Pharmacol. 1983; 16: 529–535.
    OpenUrlPubMed
  3. ↵
    Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001; 344: 1651–1658.
    OpenUrlCrossRefPubMed
  4. ↵
    Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357: 1385–1390.
    OpenUrlCrossRefPubMed
  5. ↵
    Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994; 24: 1678–1687.
    OpenUrlCrossRefPubMed
  6. ↵
    Ruffolo RR Jr, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990; 38 (suppl 2): S82–S88.
    OpenUrlCrossRefPubMed
  7. ↵
    Gretzer I, Hjemdahl P. Differences between the effects of metoprolol and prazosin on the forearm vasculature in primary hypertension. J Hypertens. 1997; 15: 1317–1326.
    OpenUrlCrossRefPubMed
  8. ↵
    Oettl K, Greilberger J, Zangger K, et al. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol. 2001; 62: 241–248.
    OpenUrlCrossRefPubMed
  9. ↵
    Huang WH, Wang Y, Askari A. (Na+/K+)-ATPase: inactivation and degradation induced by oxygen radicals. Int J Biochem. 1992; 24: 621–626.
    OpenUrlCrossRefPubMed
  10. ↵
    Guerra L, Cerbai E, Gessi S, et al. The effect of oxygen free radicals on calcium current and dihydropyridine binding sites in guinea pig ventricular myocytes. Br J Pharmacol. 1996; 118: 1278–1284.
    OpenUrlPubMed
  11. ↵
    Kitakaze M, Hori M, Takashima S, et al. Superoxide dismutase enhances ischemia-induced reactive hyperemic flow and adenosine release in dogs: a role of 5′-nucleotidase activity. Circ Res. 1992; 71: 558–566.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Kitakaze M, Minamino T, Node K, et al. Adenosine and cardioprotection in the diseased heart. Jpn Circ J. 1999; 63: 231–243.
    OpenUrlCrossRefPubMed
  13. ↵
    Kitakaze M, Minamino T, Node K, et al. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation. 1995; 92: 950–961.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Bergmeyer HU. Methods of Enzymatic Analysis. 1st ed. New York, NY: Academic Press Inc; 1963: 266–270.
  15. ↵
    Smith K, Varon HH, Race GJ, et al. Serum 5′-nucleotidase in patients with tumor in the liver. Cancer. 1965; 19: 1281–1285.
    OpenUrlCrossRef
  16. ↵
    Kitakaze M, Hori M, Morioka T, et al. Alpha1-adrenoceptor activation mediates the infarct size limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity and adenosine release. J Clin Invest. 1994; 93: 2197–2205.
    OpenUrlCrossRefPubMed
  17. ↵
    Mori H, Haruyama S, Shinozaki Y, et al. New nonradioactive microspheres and more sensitive X-ray fluorescence to measure regional blood flow. Am J Physiol. 1992; 263: H1946–H1957.
    OpenUrlPubMed
  18. ↵
    Snedecor GW, Cochran WG. Statistical Methods. Ames, Iowa: Iowa State University Press; 1972: 258–298.
  19. ↵
    Steel RGD, Torrie JH. Principles and Procedures of Statistics: A Biomedical Approach. 2nd ed. New York, NY: McGraw-Hill Publishing Co; 1980: 137–238.
  20. ↵
    Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 1995; 16 (suppl F): 38–42.
    OpenUrlAbstract
  21. ↵
    Kitakaze M, Hori M, Tamai J, et al. α1-Adrenoceptor activity regulates release of adenosine from the ischemic myocardium in dogs. Circ Res. 1987; 60: 631–639.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Brodde OE, Zerkowski HR, Borst HG, et al. Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. Eur Heart J. 1989; 10 (suppl B): 38–44.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Babbitt TG, Virmani R, Norton R Jr, et al. Adenosine administration during reperfusion after 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J. 1990; 120: 808–818.
    OpenUrlCrossRefPubMed
  24. ↵
    Parmely MJ, Zhou WW, Edwards CK, et al. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J Immunol. 1993; 151: 389–396.
    OpenUrlAbstract
  25. ↵
    Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol. 2000; 36: 2081–2089.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation
June 8, 2004, Volume 109, Issue 22
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    β-Adrenoceptor Blocker Carvedilol Provides Cardioprotection via an Adenosine-Dependent Mechanism in Ischemic Canine Hearts
    Hiroshi Asanuma, Tetsuo Minamino, Shoji Sanada, Seiji Takashima, Hisakazu Ogita, Akiko Ogai, Masanori Asakura, Yulin Liao, Yoshihiro Asano, Yasunori Shintani, Jiyoong Kim, Yoshiro Shinozaki, Hidezo Mori, Koichi Node, Soichiro Kitamura, Hitonobu Tomoike, Masatsugu Hori and Masafumi Kitakaze
    Circulation. 2004;109:2773-2779, originally published June 7, 2004
    https://doi.org/10.1161/01.CIR.0000130917.12959.04

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    β-Adrenoceptor Blocker Carvedilol Provides Cardioprotection via an Adenosine-Dependent Mechanism in Ischemic Canine Hearts
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    β-Adrenoceptor Blocker Carvedilol Provides Cardioprotection via an Adenosine-Dependent Mechanism in Ischemic Canine Hearts
    Hiroshi Asanuma, Tetsuo Minamino, Shoji Sanada, Seiji Takashima, Hisakazu Ogita, Akiko Ogai, Masanori Asakura, Yulin Liao, Yoshihiro Asano, Yasunori Shintani, Jiyoong Kim, Yoshiro Shinozaki, Hidezo Mori, Koichi Node, Soichiro Kitamura, Hitonobu Tomoike, Masatsugu Hori and Masafumi Kitakaze
    Circulation. 2004;109:2773-2779, originally published June 7, 2004
    https://doi.org/10.1161/01.CIR.0000130917.12959.04
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Heart Failure and Cardiac Disease
    • Myocardial Infarction
  • Intervention, Surgery, Transplantation
    • Pharmacology
  • Basic, Translational, and Clinical Research
    • Ischemia
    • Oxidant Stress
    • Contractile Function
    • Animal Models of Human Disease
  • Cardiology
    • Etiology
      • Acute myocardial infarction

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured